Introduction We have studied a patient with a congenital bleeding disorder and phenotypic manifestations typical of Bernard-Soulier syndrome, including giant platelets with absent ristocetin-induced von Willebrand factor binding. Two monoclonal antibodies reacting with distinct epitopes in the amino-terminal domain of the a-chain of glycoprotein (GP) Ib were used to estimate the number of GP Ib molecules on the platelet membrane. In the patient, binding of one antibody (LJ-TblO) was 50% of normal, while binding of the other (LJ-Ibl) was absent. Binding of both antibodies was reduced to -50% of normal in the mother and one sister of the propositus, and their platelets exhibited -70% of normal von Willebrand factor binding. Immunoblotting studies confirmed the presence of GP Iba, as well as GP IX, in patient platelets. Antibody LJ-Ib10, but not LJ-Ibl, could immunoprecipitate the patient's GP Iba from surfacelabeled proteins. Thus, platelets from the propositus contained a structurally and functionally altered GP Ib-IX complex lacking a specific antibody epitope and the ability to bind von Willebrand factor. In contrast, the binding of human a-thrombin to the patient's platelets was normal, and three classes of binding sites with high, intermediate, and low affinity could be detected. These studies define a distinct variant form of BernardSoulier syndrome and provide evidence, based on a naturally occurring mutant molecule, that the amino-terminal region of GP Iba contains a von Wiliebrand factor-binding domain distinct from the high affinity thrombin-binding site. Use of different monoclonal antibodies with distinct epitope specificities appears to be essential for a correct identification of variant Bernard-Soulier syndrome. (J. Clin. Invest. 1990. 86:25-31.) 
In the rare congenital bleeding syndrome first described by Bernard and Soulier (1), platelets are characterized by the pronounced decrease or absence of the glycoprotein (GP)' Tb-IX complex (2, 3), a major membrane component that serves as one ofthe two known binding sites for vWf (4) as well as a high affinity binding site for thrombin (5) . GP Tb, with an apparent molecular mass of 170 kD, is the major sialylated glycoprotein of the platelet membrane and consists of two disulfide-linked subunits, GP Iba (145 kD) and GP Tb( (22 kD) (6) . GP IX, with an apparent molecular mass of 18 kD, is a single-chain molecule and is linked to GP Tb in a noncovalent complex (7) .
The primary structures ofall three components ofthe complex have been determined (8) (9) (10) (11) . Patients with Bernard-Soulier syndrome typically show moderate to severe thrombocytopenia, with the presence of enlarged platelets on peripheral blood smears. These platelets show multiple functional defects, including altered response to thrombin stimulation (12, 13) and inability to bind vWf (14) (15) (16) . As a consequence, platelets fail to adhere to damaged vascular structures and show abnormal thrombus formation at sites of vascular injury (14) .
Bernard-Soulier syndrome has been shown to be heterogeneous in its phenotypic manifestations (17) , but structural and functional abnormalities of the GP Ib-IX complex have been poorly characterized to date. In the present communication we describe a patient whose platelets contained a dysfunctional GP Tb molecule that failed to bind vWf but expressed normal interaction with thrombin. In addition to the defective vWfbinding capacity, the platelets of this patient failed to express the epitope of a monoclonal anti-GP Tb antibody that has previously been shown to react with the amino-terminal region of the a-chain (18) . These findings, while clearly defining a distinct variant form of Bernard-Soulier syndrome, provide evidence based on a naturally occurring mutant molecule that elements essential for vWf binding reside in the amino-terminal domain of GP Iba, as previously suggested using other experimental approaches (19, 20) , and are distinct from the thrombin-binding site. Moreover, they demonstrate that the correct identification of variant Bernard-Soulier syndrome may require the use of monoclonal anti-GP Tb antibodies of distinct epitope specificity.
Methods
Blood samples were obtained from patients and normal volunteers with their informed consent and in accordance with the Declaration of Helsinki. They had taken no medication for at least 2 wk. Bleeding time and platelet count were performed as previously described (21 The anti-GP lb monoclonal antibodies used in this study (U-IbI and LJ-IblO) were prepared and characterized as published in detail elsewhere (18) . Both react with the a-chain of GP lb and recognize distinct epitopes (8, 18) . The murine monoclonal antibody LJ-RA8 (specific for GP IX; see Results) was obtained and selected according to a published procedure (18) after immunization with reduced and alkylated GP Ib-IX complex prepared as reported (18) . Purified IgG was obtained from mouse ascitic fluid using staphylococcal protein A coupled to Sepharose 4B-CL (Sigma Chemical Co.) or DEAE-AffiGel blue chromatography (Bio-Rad Laboratories, Richmond, CA) as described previously (25, 26) . Immunoblotting studies were performed following published methods (18, 27) ; the monoclonal antibodies used were LJ-lb O and U-RA8, while U-Ibl failed to react with transblotted protein.
The method used for the purification of vWf from cryoprecipitate has been published in detail elsewhere (28) . Characterization of the purified vWf was performed as previously described (23 (30) . For all the curves analyzed in the course of these studies, the best fit of experimental data was obtained without a nonsaturable component in the total binding isotherm; thus, nonspecific binding was assumed to be 0 for all curves. Flow cytometric analysis was performed on platelet-rich plasma diluted with homologous platelet-poor plasma to obtain a platelet count of 5 X 107/ml. 100 ul of the platelet suspension was then incubated with increasing concentrations of monoclonal antibody U-IblO for 45 min at 37°C. Goat anti-mouse IgG conjugated to FITC (Ortho Pharmaceutical, Raritan, NJ) was then added and incubated at 37°C for 45 min. Fluorescent cells were analyzed using a Spectrum III flow cytometer (Ortho Pharmaceutical) after further dilution of the sample (1:10) in a buffer composed of20 mM sodium phosphate and 150 mM sodium chloride, pH 7.3. In selected experiments the blood used for flow cytometric analysis was drawn into anticoagulant containing soybean trypsin inhibitor (see above).
Results
Case report. The propositus (D.V.G.) had been previously described as having classical Bernard-Soulier syndrome, a conclusion based on the results of platelet-binding studies performed with monoclonal antibody AP-1. According to these previous findings, antibody binding was absent in the propositus and decreased to -50% of normal in the parents and four sisters, who were considered to be heterozygotes (21) .
Abnormal expression ofa GP Iba epitope in thepropositus. Two monoclonal antibodies, U-Ib1 and LJ-Lb 0, which recognize distinct epitopes in the a-chain of GP lb (18) , were used for these experiments. In particular, UJ-Ib reacts with a conformational epitope present only in native GP lb and located within the first 293 amino-terminal residues (8, 18) ; it completely inhibits vWfbinding to GP Ib (18) , but has no effect on thrombin binding (unpublished observation). LJ-Ib O reacts with an epitope present in native as well as denatured, reduced, and S-carboxymethylated a-chain, and located between residues Ala238 and Alg293 (8, 18) ; it has no effect on ristocetinmediated vWf binding to platelets (18) , but inhibits thrombin binding (unpublished observation). The interaction of both antibodies with patient platelets was decreased, but the degree ofabnormality varied considerably depending on the antibody used. There was no detectable binding of LJ-Ib 1, whereas binding of LJ-IblO corresponded to -50% of normal (Table  I) . Similar results were also observed when studies were performed immediately after collection of blood in anticoagulant containing aprotinin, EDTA, and soybean trypsin inhibitor (Table I) . Without these precautions, a decrease of 15-20% in the binding of monoclonal anti-GP lb antibodies to normal platelets may occur within 2-3 h from blood collection. In contrast to the findings in the propositus, both antibodies bound concordantly to platelets obtained from the mother and one sister of the patient, and the number of molecules bound corresponded to -50% of normal (Table I) . With both antibodies, the dissociation constants calculated for binding to platelets from the propositus or his relatives were in close agreement with those calculated for normal platelets (Table I) .
Monoclonal antibody LJ-Ib O reacted with normal GP Ib a-chain blotted onto nitrocellulose after polyacrylamide gel electrophoresis in the presence of SDS (Fig. 1) , and was thus used to study the electrophoretic mobility ofthe patient GP lb a-chain. Two bands could be detected. One, with an apparent molecular mass of 145 kD, was similar to normal GP-Iba; the other, with a molecular mass of 105 kD, corresponded to a band seen in normal platelets only when a high cQncentration of membrane proteins was applied to the gels (Fig. 1) . The pattern seen in platelets from the patient's mother and sister was similar, although relatively smaller amounts ofthe 105-kD bands were seen. Immunoblotting was also performed with monoclonal antibody LJ-RA8, which recognizes an epitope located on GP IX (Fig. 2) . One band was seen with platelets from the propositus and his mother, showing a mobility similar to that of normal GP IX (Fig. 2) . Immunoprecipitation of surface-labeled glycoproteins demonstrated abnormalities in agreement with those seen in immunoblotting studies. With patient platelets, antibody LJ-lb O precipitated two bands ofsimilar intensity with apparent molecular masses of 145 and 105 kD, respectively; with normal platelets, only the band at 145 kD was distinctly evident (Fig. 3 ). An additional band with an apparent molecular mass of 38 kD was seen in the sample from the propositus but not in normal, while another minor band with an apparent molecular mass of 70 kD in normal showed decreased intensity and faster mobility (apparent molecular mass of 66 kD) in the propositus (Fig. 3) . The exact nature of these two polypeptides, as well as of two bands larger than reduced GP lba (Fig.  3) , remains to be identified. Immunoprecipitation with antibody LJ-lbl gave results identical to LJ-lb O in normal platelets, whereas no detectable immunoprecipitates were observed with platelets from the propositus (not shown). The procedure followed for this experiment was similar to that described in the legend to Fig. 1 Binding of vWf and a-thrombin to platelets. Binding of 1251-vWf to washed platelets in the presence of ristocetin (0.8 mg/ml) was undetectable in the propositus, while it was decreased to -70% of normal in his mother and sister (Table II) . In contrast, binding isotherms obtained with '251-labeled athrombin demonstrated that platelets from the propositus, like normal platelets, expressed three classes of binding sites with high, moderate, and low affinity (Table III) . This was in contrast to the results obtained with platelets from the patient with classical Bernard-Soulier syndrome (patient B.L., reference 21), which failed to express high affinity binding sites (Table III).
kD tibody, U-Ib0O, which has no inhibitory effect on ristocetinmediated vWf binding (18) but is known to inhibit the high affinity thrombin-binding sites on normal platelets (De Marco, L., M. Mazzucato, and Z. M. Ruggeri, manuscript in preparation). The present results, therefore, support with the example of a naturally occurring mutant the concept that the aminoterminal region of GP Iba contains two domains essential for vWf binding (19, 20) and high affinity thrombin binding (5), each distinctly related to the epitopes of antibodies UJ-Ibl and J-Ib 1O, respectively. Only the vWf-binding domain is structurally and functionally altered in the patient described here, who exhibits a clear dissociation of two typical abnormalities of patients with Bernard-Soulier syndrome, namely, the defective interaction with vWf and thrombin (12) (13) (14) (15) (16) .
The availability of specific anti-GP lb monoclonal antibodies has led to the recommendation of their use for the diagnosis of Bernard-Soulier syndrome (31) . The present results clearly show that, depending on the epitope specificity of the antibodies used, there is the possibility of reaching significantly different conclusions as to the presence and functionality of platelet GP Ib. For example, this same propositus was previously identified as a typical Bernard-Soulier patient with absent platelet GP Ib (21) as judged by lack of platelet reactivity with antibody AP-1, a well-characterized anti-GP lb antibody that inhibits vWf interaction with platelets (31) . In this regard, the results previously observed with AP-1 are identical to those obtained in the course of these studies with LJ-Ibl. Nevertheless, the presence of GP lb in the platelets of this patient has now been demonstrated using another antibody that reacts with an epitope not directly related to the vWf binding site. These findings provide an important example that, when using immunological methods of detection, it is necessary to perform studies with antibodies reacting with different epitopes before reaching conclusions about the presence or absence of a certain antigen. In fact, the results obtained here with regard to platelet GP lb are likely to apply to any other membrane glycoprotein. This may be particularly important in the case of platelets deficient in a certain function, like vWf binding in the case presented here, when the antibodies used inhibit the same function in normal platelets. In fact, these antibodies may fail to detect abnormal molecules when the corresponding epitope is closely related to the altered functional domain.
The exact nature of the structural abnormality and underlying genetic defect of the mutant GP lb molecule described here remain unknown at present. As a matter of fact, even though the defective functional domain and corresponding LJ-Ibl epitope have both been located in the a-chain of GP lb (18) (19) (20) , it remains possible, although unlikely, that other components of the complex, like the #-chain of GP Ib or GP IX, may themselves be abnormal and responsible for the defect in GP Iba through conformational effects. Nevertheless, the presence in the patient's platelets of immunoreactive GP Iba of heterogeneous molecular mass, with 145-and 105-kD species, supports the concept of an intrinsic defect in this glycoprotein. The origin of the smaller GP Iba molecule remains undefined at present, but the findings presented here are consistent with the concept that it is proteolytically derived from the normal-sized species. In fact, both molecules must share the same structural abnormality since neither of them reacts with antibody LJ-Ib . Moreover, both species are immunoprecipitated by antibody LJ-IblO from surface-labeled platelets; thus, they are both membrane expressed. It is conceivable, therefore, that the structural abnormality responsible for the altered vWf-binding function and the loss of the LJ-Ibl epitope determines an increased susceptibility to proteolysis at a specific site in the amino-terminal domain of GP Iba, with cleavage of a fragment of -40 kD. The existence of a protease-sensitive region in GP Iba is, indeed, suggested by the observation that small amounts of a cleaved l00-kD species have been found in purified preparations of normal GP Ib-IX complex (32) , in agreement with findings reported here (Fig.  1) . Interestingly, a fragment of -40 kD could be immunoprecipitated by LJ-IbIO from surface-labeled proteins of patient platelets. This fragment may represent the amino-terminal portion ofGP Iba, which may remain linked to the rest of the molecule after cleavage because of the existence of intrachain disulfide bonds in that region of the a-chain (8, 19, 20) . This hypothesis will have to be tested with future experiments. While proteolysis in vitro is difficult to rule out in spite of the use of a mixture of protease inhibitors, it is likely that generation of the smaller GP Iba species is an in vivo proteolytic event on a structurally abnormal mutant molecule. Other possible explanations for the presence of the smaller GP Iba species, like incomplete glycosylation or synthesis directed by an abnormal mRNA, cannot be ruled out at present, but appear less likely in view of the fact that both GP Iba species detected in the patient's platelets share the same antigenic defect.
The modality of genetic transmission of this new variant form of Bernard-Soulier syndrome remains unresolved. Typical patients show multiple defects ofplatelet membrane glycoproteins (2, 1 1) and lack, among others, three proteins (GP Iba, GP lbj3, and GP IX) that are the product of distinct genes (9-11) and form a complex in normal platelets (7) . This may be the consequence of a single genetic lesion if one postulates that absence of one component of the complex may result in rapid degradation of the others, a situation similar to that proposed as an explanation for the dual glycoprotein defect in Glanzmann thrombasthenia (33) (34) (35) (36) . The situation in this family appears uniquely different, since the propositus exhibited decreased levels of structurally altered GP Iba, while two relatives available for study had decreased levels of an apparently normal molecule. A simple explanation for this phenotypic pattern is that the patient may have inherited two different altered alleles from his parents. The phenotype in the mother is compatible with a heterozygous state characterized by the presence of one normal and one null allele, leading to decreased expression of an otherwise normal molecule. The father could be heterozygous with one normal allele and one abnormal allele responsible for the structural defect. This would predict that the father has normal GP Iba expression as measured by J-Ib 1O, but only 50% as measured by LJ-Ib1, a fact that could not be verified experimentally since the father was not available for additional studies. In the offspring, then, the daughter would have inherited the null maternal allele and the normal paternal allele, thus exhibiting the same phenotype as the mother. The propositus, on the other hand, would have inherited the null maternal allele and the abnormal paternal allele, thus exhibiting decreased expression of a structurally and functionally abnormal molecule.
In contrast with this hypothesis is the finding that the smaller GP Iba species (the marker of structural abnormality in the patient) could be detected in both mother and sister of the propositus, as shown in Fig. 1 
